Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix monthly dosing versus Lupron Depot in prostate cancer
2005-005595-33Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Primary efficacy criteria. Started Jan 2006; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005595-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005595-33.